40
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Dice (Dexamethasone, Ifosfamide, Cisplatin, Etoposide) as Salvage Therapy in Non-Hodgkin's Lymphomas

, , , , &
Pages 123-129 | Received 01 Sep 1994, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

JJ Biagi, KE Herbert, C Smith, E Abdi, M Leahy, C Falkson, M Wolf, H Januszewicz, JF Seymour, K Richards, JP Matthews, B Dale & HM Prince. (2005) A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leukemia & Lymphoma 46:2, pages 197-206.
Read now
M. Reiser, R. Schnell, G. Straub, P. Borchmann, M. Wilhelm, R. Übelacker, B. Wörmann, R. Münch, V. Diehl & A. Engert. (1998) DIZE (Dexamethasone, Idarubicin, and Continuous Infusion of Ifosfamide and Etoposide): an Effective and Well-Tolerated New Regimen for Patients with Relapsed Lymphoma. Leukemia & Lymphoma 31:3-4, pages 359-366.
Read now

Articles from other publishers (9)

Ji Young Moon, Seung-Woo Baek, Hyewon Ryu, Yoon-Seok Choi, Ik-Chan Song, Hwan-Jung Yun, Deog-Yeon Jo, Samyong Kim & Hyo Jin Lee. (2017) VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. Medicine 96:4, pages e5942.
Crossref
Danuta Pentak. (2014) Physicochemical properties of liposomes as potential anticancer drugs carriers. Interaction of etoposide and cytarabine with the membrane: Spectroscopic studies. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 122, pages 451-460.
Crossref
Michael Crump, Tara Baetz, Stephen Couban, Andrew Belch, Deborah Marcellus, Kang Howson‐Jan, Kevin Imrie, Robert Myers, Grenfell Adams, Keyue Ding, Nancy Paul, Lois Shepherd, Jose Iglesias & Ralph Meyer. (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma. Cancer 101:8, pages 1835-1842.
Crossref
Amr El Weshi, Muhammad Memon, Madras Raja, Shouki Bazarbashi, Mohamed Rahal, Mahmoud El Foudeh, Chandrashekhar Pai, Ayman Allam, Ibrahim El Hassan & Adnan Ezzat. (2004) VIP (Etoposide, Ifosfamide, Cisplatin) in Adult Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors. American Journal of Clinical Oncology 27:5, pages 529-534.
Crossref
CI Chen, D Roitman, R Tsang, AK Stewart, A Keating & M Crump. (2002) ‘Relative’ chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplantation 30:12, pages 885-891.
Crossref
John F. Seymour, Andrew P. Grigg, Jeff Szer & Richard M. Fox. (2002) Cisplatin, fludarabine, and cytarabine. Cancer 94:3, pages 585-593.
Crossref
N. Haim, K. Drumea, R. Epelbaum & M. Ben-Shahar. (1999) Dexamethasone, Cytarabine, Ifosfamide, and Cisplatin as Salvage Therapy in Non-Hodgkin Lymphoma. American Journal of Clinical Oncology 22:1, pages 47-50.
Crossref
Nissim Haim, Menachem Ben-Shahar, David Faraggi, Avital Tsuri-Etzioni, Michelle Leviov & Ron Epelbaum. (1997) Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-hodgkin's lymphoma. Cancer 80:10, pages 1989-1996.
Crossref
C. Girouard, J. Dufresne, K. Imire, A.K. Stewart, J. Brandwein, H.M. Prince, D. Pantolony, A. Keating & M. Crump. (1997) Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Annals of Oncology 8:7, pages 675-680.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.